Goldman Sachs analyst Bruno Amorim maintains Cemex (NYSE:CX) with a Neutral and raises the price target from $5.2 to $5.9.
Medicenna Announces New Clinical Data Providing Preliminary Evidence Of MDNA11’s Single Agent Anti-Cancer Activity In The Phase 1/2 ABILITY Study
-- Tumor control was achieved in four of ten evaluable patients with advanced solid tumors unresponsive to other treatments enrolled in the ABILITY Study’s low and mid-stage dose escalation cohorts
--
